share_log

Prime Medicine (NYSEARCA:PRME) Trading Up 2.1%

Prime Medicine (NYSEARCA:PRME) Trading Up 2.1%

Prime Medicine(NYSEARCA：PRME)股價上漲2.1%
Financial News Live ·  2022/11/18 01:32

Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating)'s stock price was up 2.1% during mid-day trading on Thursday . The company traded as high as $18.61 and last traded at $18.61. Approximately 15 shares traded hands during trading, a decline of 100% from the average daily volume of 540,992 shares. The stock had previously closed at $18.22.

Prime Medicine，Inc.(NYSEArca：PRME-GET Rating)股價週四午盤上漲2.1%，最高報18.61美元，尾盤報18.61美元。交易中約有15股股票易手，較日均成交量540,992股下跌100%。該股此前收盤報18.22美元。

Analyst Upgrades and Downgrades

分析師升級和下調評級

A number of research analysts have recently issued reports on PRME shares. Jefferies Financial Group began coverage on Prime Medicine in a research note on Monday. They set a "buy" rating and a $25.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Prime Medicine in a report on Monday. They set a "neutral" rating and a $22.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of Prime Medicine in a report on Monday. They set an "overweight" rating and a $27.00 target price for the company. Finally, Morgan Stanley began coverage on shares of Prime Medicine in a report on Monday. They set an "equal weight" rating and a $23.00 target price for the company.

一些研究分析師最近發佈了關於PRME股票的報告。傑富瑞金融集團(Jefferies Financial Group)週一在一份研究報告中開始報道Prime Medicine。他們為該股設定了“買入”評級和25.00美元的目標價。高盛在週一的一份報告中開始報道春華醫藥的股票。他們為該公司設定了“中性”評級和22.00美元的目標價。摩根大通(JPMorgan Chase&Co.)週一在一份報告中開始報道Prime Medicine的股票。他們為該公司設定了“增持”評級和27美元的目標價。最後，摩根士丹利在週一的一份報告中開始對春華醫藥的股票進行報道。他們為該公司設定了“同等權重”的評級和23.00美元的目標價。

Get
到達
Prime Medicine
優質醫療
alerts:
警報：

Prime Medicine Trading Up 3.8 %

Prime Medicine股價上漲3.8%

The company's fifty day moving average price is $19.55 and its 200-day moving average price is $19.99.

該公司的50日移動均線價格為19.55美元，200日移動均線價格為19.99美元。

Insider Transactions at Prime Medicine

Prime Medicine的內幕交易

In other Prime Medicine news, Director Thomas Cahill purchased 400,000 shares of the company's stock in a transaction dated Monday, October 24th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,800,000.00. Following the purchase, the director now directly owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The acquisition was disclosed in a legal filing with the SEC, which is available through
在Prime Medicine的其他新聞方面，董事託馬斯·卡希爾在10月24日星期一的一筆交易中購買了400,000股該公司股票。這些股票是以每股17.00美元的平均價格收購的，總交易額為6800,000.00美元。收購完成後，董事現在直接擁有5305679股公司股票，價值約90,196,543美元。此次收購是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過
the SEC website
美國證券交易委員會網站
. In other news, major shareholder 2019 Gp L.L.C. Gv bought 800,000 shares of the stock in a transaction that occurred on Monday, October 24th. The shares were bought at an average price of $17.00 per share, for a total transaction of $13,600,000.00. Following the purchase, the insider now owns 11,522,248 shares in the company, valued at $195,878,216. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through
。在其他新聞方面，大股東2019 GP L.L.C.GV在10月24日星期一的一筆交易中購買了80萬股該股。這些股票是以每股17.00美元的平均價格購買的，總交易額為13,600,000.00美元。收購完成後，這位內部人士現在擁有該公司11,522,248股，價值195,878,216美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過
the SEC website
美國證券交易委員會網站
. Also, Director Thomas Cahill bought 400,000 shares of the stock in a transaction that occurred on Monday, October 24th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $6,800,000.00. Following the purchase, the director now owns 5,305,679 shares in the company, valued at approximately $90,196,543. The disclosure for this purchase can be found
。此外，在10月24日(星期一)的一筆交易中，董事託馬斯·卡希爾購買了400,000股該股。這些股票是以每股17.00美元的平均價格購買的，總交易額為6,800,000.00美元。收購完成後，董事現在擁有該公司5305679股，價值約90,196,543美元。關於這次購買的披露可以找到
here
這裏
.
.

Prime Medicine Company Profile

優質醫藥公司簡介

(Get Rating)

(獲取評級)

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Prime Medicine，Inc.是一家生物技術公司，通過部署基因編輯技術提供基因療法來治療疾病。它為Prime Edants提供了Prime Editor蛋白質和pegRNA，前者包括CaS蛋白質和逆轉錄酶之間的融合；後者將Prime Editing定位於特定的基因組位置，並提供對目標DNA序列進行所需編輯的模板。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
  • BJ's Wholesale Club: Beware The Sell-Side
  • The Next Catalyst For Mullen Automotive Stock Is December 23rd
  • NVIDIA's Rally Picks Up Pace Into Year End
  • Nothing Micro About Super Micro Computer's Price & Earnings Gains
  • Why Are Bears Still Going Short on AGNC Investment?
  • 免費獲取StockNews.com關於Prime Medicine(PRME)的研究報告
  • BJ‘s批發俱樂部：當心賣方
  • 馬倫汽車股票的下一個催化劑是12月23日
  • NVIDIA的拉力賽加快了年底的步伐
  • 超微計算機的價格和收益收益並不是微不足道的
  • 為什麼貝爾斯登仍在做空AGNC投資公司？

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

接受《頂級醫學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Prime Medicine和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論